Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

BACKGROUND: Cetuximab and bevacizumab reportedly improve the survival of patients with metastatic colorectal cancer (mCRC), but their most effective sequence of administration is unknown. The aim of this study was to compare the survival of patients with mCRC treated with cetuximab after bevacizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yasuyoshi, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648607/
https://www.ncbi.nlm.nih.gov/pubmed/26648737
http://dx.doi.org/10.2147/OTT.S89241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648607/
https://www.ncbi.nlm.nih.gov/pubmed/26648737
http://dx.doi.org/10.2147/OTT.S89241

Ejemplares similares